Tag Archives: COVID-19

Borrowing from Mosquitos – A Potential Broad-Spectrum Antiviral

A team of researchers at the National Institute of Environmental Health Sciences (NIEHS) have found a promising antiviral in the strangest place – a protein called AEG12 found in the gut of mosquitos. This recent study lead by Dr. Alexander Foo found that AEG12 strongly inhibits the family of viruses that cause Yellow Fever, Dengue, West Nile, and Zika, and that the protein may also inhibit their distant relative: coronaviruses. Although the virus-killing AEG12 protein sounds promising, it may still be a long time before its safe to use in humans.

The Aedes aegypti mosquito, which can carry viruses such as Yellow Fever, Dengue, and Zika (Image source)

Foo and His Findings

Scientists have long been on the hunt for effective antivirals, and researchers like Dr. Foo have been making great progress in the field. Foo’s recent study showed that AEG12 was effective at killing flaviviruses (such as Dengue and Zika) but was less effective at killing coronaviruses. Using methods and software tools for understanding how proteins work and specialized laboratory techniques to study viruses, the team was able to piece together how AEG12 is such a successful virus-destroyer.

Flaviviruses are enveloped: meaning that each virus particle is surrounded by a membrane. The infection process, in the video below, shows how the virus must first attach to the surface a human cell (0:28) and then fuse its membrane with ours to get inside (1:12).

Essentially, the AEG12 protein carries little membrane pieces of its own, which are different from the type found in the virus’ membrane. When it comes across a virus, AEG12 trades its pieces for the virus’. Once enough chunks are swapped out, the virus’ membrane becomes unstable and can’t fuse with our cells: effectively “killing” the virus.

The AEG12 protein swaps out viral membrane pieces for unstable pieces (Image source)

Even though AEG12’s virus-killing abilities sound promising, Foo’s team found that AEG12 breaks apart red blood cells. Although useful to a mosquito that needs to digest a blood meal, use of AEG12 in humans would lead to a very serious blood disorder that could be fatal if left untreated.

There is Still Hope

So, AEG12 isn’t safe for use in humans… Yet. With some clever solutions and careful bioengineering, further research could find a way to modify AEG12 so that it targets viruses and ignores human cells. The development of a drug or molecule effective against enveloped viruses could save lives across the globe – addressing not only the headlining COVID-19 pandemic, but the ongoing epidemics as well.

-Maya Bird

A ‘Viral’ Testing Kit: ID Now COVID-19

THE PROBLEM 

Every single one of us can help control the spread of the COVID-19 pandemic. Whether we’re humming “Happy Birthday” twice every time we wash our hands, or facetiming our friends instead of meeting up, we can all adopt changes that will help us get back to our normal lives sooner. Another thing we can do is to get tested, should we suspect COVID-19 infection.

When to get tested for COVID-19
Credit: BC Centre for Disease Control, www.bccdc.ca

Getting tested is easier said than done. It’s an inconvenient drive-in, followed by a period of self-isolation until results come back, which can take up to four days.

Besides just being tedious, this lengthy processing time has other concerns. A study found that patients infected with COVID-19 are most infectious within the first five days of initial symptoms. If results aren’t coming back soon after testing, they become less effective at stopping the virus right in its tracks. 

THE SOLUTION

This is where Abbott Laboratories steps up! Having already developed reliable testing tools for influenzas A&B, strep A, and respiratory syncytial virus, it was only a matter of time before COVID-19 testing apparatuses were developed. In early 2020, Abbott developed the ID Now COVID-19 Rapid Nucleic Acid Amplification Test, and launched for distribution in the US after receiving approval for emergency use from the FDA that year in March. Shortly after, Health Canada provided approval of use in October 2020.

NO IMAGEAbbott’s ID Now COVID-19 Test
Credit: abbot.com

This Rapid Nucleic Acid Amplification Test takes nasal swabs from individuals, and amplifies the viral ribonucleic acid (essentially a COVID-19 nametag) hundreds of millions of times until it’s detectable by their system. What’s more, this impressive amplification process is done is a matter of minutes, and test results are returned within 13 minutes – hence the term rapid! The entire process is summarized in this short video from Abbott.

How ID Now COVID-19 Works
Credit: Abbott, www.youtube.com

It’s normal to have some doubt when the current gold standard testing protocol in Canada (RT-PCR) takes 6–8 hours.

Abbot’s clinical trial on 1003 subjects reported a similar accuracy using their ID Now machine compared to current lab PCR testing. This study was done in a controlled clinical setting, so these results are not representative of the real world.

Dr. Gary Procop, a director of virology at the Cleveland Clinic, found that ID Now missed up to 15% of COVID-19 cases in infected patients, that other tests were able to catch! He states that “just because we need something put out emergently, doesn’t mean we should put out something that doesn’t work appropriately.” In a response, the FDA stated that they will continue to track these tests and take action if necessary. Check out more of the interview below.

Questions About Accuracy of Coronavirus Tests
Credit: CNN, www.cnn.com

This is Abbott’s response to the ‘rapidly’ changing world. They have provided frontline workers with rapid testing, but whether or not they can combat COVID-19 as quickly as their tests do remains a question.

~William Lee

Quote

A ‘Viral’ Testing Kit: ID Now COVID-19

THE PROBLEM

All around the world, new COVID-19 testing centres are constantly being opened in response to the growing number of victims. These testing centres provide information about one’s diagnosis, but often through a stressful and lengthy experience. Testing centers around Canada experience wait times of up to 2 hours, and usually requires a minimum of at least 48 hours before results become available. This is a problem.

COVID-19 Testing Centre in North Vancouver
Credit: Jane Seyd, www.nsnews.com

Besides just being tedious, this lengthy processing time has other concerns. The Director of Abbott, Norman Moore describes it:

“You’re the most infectious early on—and if we don’t have results in that timely fashion, what does it help if a molecular test comes back two weeks later?”

THE SOLUTION

This is where Moore and his team at Abbott steps in. Having already developed reliable testing tools for influenzas A&B, strep A, and respiratory syncytial virus, it was only a matter of time before COVID-19 testing apparatuses were developed. In early 2020, Abbott developed the ID Now COVID-19 Rapid Nucleic Acid Amplification Test, and launched for distribution in the US after receiving approval for emergency use from the FDA that year in March. Shortly after, Health Canada provided approval of use in October 2020.

NO IMAGEAbbott’s ID Now COVID-19 Test
Credit: abbot.com

This Rapid Nucleic Acid Amplification Test takes nasal swabs from individuals suspected with COVID-19, and exposes the viral RNA packed under the outer envelope of the SARS-CoV-2 virus in an acidic solution at 56⁰ C. Just as it is written in the name, it then takes the viral RNA and amplifies it hundreds of millions of times until it is detectable by the system, and what’s more this impressive amplification process is done is a matter of minutes, and test results are returned within 13 minutes.

A Typical Nasal Swab
Credit: U.S. Pacific Fleet, www.flickr.com

It’s normal to have some doubt when the current gold standard testing protocol in Canada (RT-PCR) takes 6-8 hours on average. We can compare the accuracy of an ID Now diagnosis to PCR lab tests by considering sensitivity and specificity.

  • Sensitivity measures the proportion of people with COVID that are correctly identified
  • Specificity measures the proportion of people without COVID that are correctly identified

Abbot’s clinical trial on 1003 subjects reported an average sensitivity of 93.3% and specificity of 98.4%. This is comparable to a separate meta-analysis on lab PCR testing which determined an average sensitivity of 98%, and no reported specificity. Note that these numbers are dependent on many factors, and are often higher than what is seen in the real world. This shows that ID Now can be an effective solution to rapid testing, but that results should be taken as preliminary and confirmed with other molecular assessments if results are not consistent with one’s symptoms.

This is Abbott’s response to the ‘rapidly’ changing world. They have provided frontline workers across North America with rapid testing, but whether or not they can combat COVID-19 as quickly as their tests do remains a question.

~William Lee